Ikarian Capital, LLC Allakos Inc. Call Options Transaction History

Ikarian Capital, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 13, 2022	SELL	$5.08 - $9.81 $1.11 Million - $2.14 Million	-218,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$8.55 - $111.89 $574,560 - $7.52 Million	67,200 Added 44.56%	218,000 $2.14 Million
Q3 2021 Nov 15, 2021	BUY	$76.53 - $110.43 $5.3 Million - $7.65 Million	69,300 Added 85.03%	150,800 $16 Million
Q2 2021 Aug 16, 2021	BUY	$85.37 - $114.1 $3.29 Million - $4.39 Million	38,500 Added 89.53%	81,500 $6.96 Million
Q1 2021 May 17, 2021	SELL	$109.73 - $153.66 $1.72 Million - $2.41 Million	-15,700 Reduced 26.75%	43,000 $4.94 Million
Q4 2020 Feb 12, 2021	BUY	$79.58 - $152.45 $2.28 Million - $4.38 Million	28,700 Added 95.67%	58,700 $8.22 Million
Q1 2020 May 15, 2020	SELL	$44.49 - $93.39 $5.73 Million - $12 Million	-128,800 Reduced 81.11%	30,000 $1.34 Million
Q4 2019 Jan 31, 2020	BUY	$66.49 - $137.73 $10.6 Million - $21.9 Million	158,800 New	158,800 $15.1 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.